Quantcast
Published On: Thu, Nov 28th, 2013

Baxter recalls Nitroglycerin injection due to particulate matter risk

Baxter International Inc. announced today it has initiated a voluntary recall of one lot of Nitroglycerin in 5% Dextrose Injection due to particulate matter found in one vial. If infused, particulate matter could lead to potential venous and/or arterial thromboembolism (blockage of blood vessels.) Other adverse events associated with injection of particulate matter include inflammation due to foreign material, particularly in the lungs, and local irritation of blood vessels.

Nitroglycerin

Nitroglycerin

There have been no reported adverse events associated with this issue to date. The financial impact of this recall is not material to Baxter.

Nitroglycerin in 5% Dextrose Injection (Intravenous) is indicated for treatment of peri-operative hypertension (treatment of high blood pressure before, during and after surgery); for control of congestive heart failure in the setting of acute myocardial infarction (during a new onset heart attack, a weakness of the heart muscle may cause fluid to build up in the lungs and other body tissues); for treatment of angina pectoris (chest pain) in patients who have not responded to sublingual nitroglycerin and β-blockers (beta blocker drugs); and for induction of intraoperative hypotension (low blood pressure during surgery).

Baxter’s Nitroglycerin in 5% Dextrose Injection is packaged in 250 mL glass containers, with 12 glass containers per carton. The affected product code is 1A0694, and the affected lot number is G105197. Product affected by this recall was distributed to healthcare centers and distributors in Colombia, Saudi Arabia and the United States.

Baxter is notifying customers, who are being directed not to use product from the recalled lot. Customers should locate and remove all affected product from their facility. The affected lot was distributed to customers between January 17, 2013, and October 10, 2013. Unaffected lot numbers can continue to be used according to the instructions for use. Affected product should be returned to Baxter for credit by contacting Baxter Healthcare Center for Service at 1-888-229-0001 between the hours of 7:00 a.m. and 6:00 p.m., Central Time. Unaffected lots of product are available for replacement.

Press Release

On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- Writer, Co-Founder and Executive Editor of The Global Dispatch. Robert has been covering news in the areas of health, world news and politics for a variety of online news sources. He is also the Editor-in-Chief of the website, Outbreak News Today and hosts the podcast, Outbreak News Interviews on iTunes, Stitcher and Spotify Robert is politically Independent and a born again Christian Follow @bactiman63

Tags
Displaying 2 Comments
Have Your Say
  1. Hepatitis C drug, Sovaldi, receives FDA nod – The Global Dispatch | TodayJournals.Com says:

    […] […]

  2. Hepatitis C drug, Sovaldi, receives FDA nod – The Global Dispatch | Hot Breaking News says:

    […] […]

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Sign up for our Weekly Newsletter



Categories

Archives

At the Movies

Pin It